期刊
BRAIN
卷 144, 期 -, 页码 1230-1246出版社
OXFORD UNIV PRESS
DOI: 10.1093/brain/awab020
关键词
glioblastoma; chemoresistance; purine biosynthesis; cellular plasticity
资金
- National Institute of Neurological Disorders and Stroke [1R01NS096376, 1R01NS112856]
- American Cancer Society grant [RSG-16-034-01-DDC, R01NS095642]
- National Institute of Cancer [R00CA194192]
- National Institute of Medicine grant [R01GM135587, R35CA197725, P50CA221747]
Glioblastoma is a primary brain cancer with a near 100% recurrence rate. A molecular circuit involving the interaction between ARL13B and IMPDH2 has been identified, which affects the efficacy of chemotherapy.
Glioblastoma is a primary brain cancer with a near 100% recurrence rate. Upon recurrence, the tumour is resistant to all conventional therapies, and because of this, 5-year survival is dismal. One of the major drivers of this high recurrence rate is the ability of glioblastoma cells to adapt to complex changes within the tumour microenvironment. To elucidate this adaptation's molecular mechanisms, specifically during temozolomide chemotherapy, we used chromatin immunoprecipitation followed by sequencing and gene expression analysis. We identified a molecular circuit in which the expression of ciliary protein ADP-ribosylation factor-like protein 13 (ARL13B) is epigenetically regulated to promote adaptation to chemotherapy. lmmuno-precipitation combined with liquid chromatography-mass spectrometry binding partner analysis revealed that that ARL13B interacts with the purine biosynthetic enzyme inosine-5'-monophosphate dehydrogenase 2 (IMPDH2). Further, radioisotope tracing revealed that this interaction franc Lions as a negative regulator for purine salvaging. Inhibition of the ARL13B-IMPDH2 interaction enhances temozolomide-induced DNA damage by forcing glioblastoma cells to rely on the purine salvage pathway, Targeting the ARL13B-IMPDH2 circuit can be achieved using the Food and Drug Administration-approved drug, mycophenolate mofetil, which can block IMPDH2 activity and enhance the therapeutic efficacy of temozolomide. Our results suggest and support clinical evaluation of MMF in combination with temozolomide treatment in glioma patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据